Neuroglee Health and Mayo Clinic collaborate to offer AI-driven virtual cognitive and dementia care for patients, alongside dedicated support for their caregivers. The partnership expands access to specialized, technology-enhanced healthcare services for dementia management. Neuroglee focuses on value-based care models in this space.
Neuroglee Health introduces technology-driven dementia and cognitive care solutions designed for home use. The company partners strategically to enhance accessibility to personalized, high-touch care for patients. These solutions aim to support caregivers and improve quality of life through digital health innovations.
Neuroglee Health joins the **CMS GUIDE Model**, an 8-year initiative to redefine dementia care delivery, coordination, and reimbursement for Alzheimer’s patients and caregivers. The company supports the program’s goals through its cognitive care solutions. Neuroglee Health also announced a company name evolution as part of this milestone.
Neuroglee Therapeutics secures $10M in Series A funding to expand digital therapeutic solutions for neurodegenerative disease patients. The capital, led by Openspace Ventures and EDBI, will support the launch of virtual neurology clinics and the company’s relocation to Boston. Backers include Eisai Co., former Mundipharma CEO Ramen Singh, and Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu.
Neuroglee Therapeutics secures **$10 million in Series A funding** to advance **personalized digital therapeutics (DTx) and virtual care** for Alzheimer’s disease. The company plans to launch **first-of-their-kind virtual neurology clinics** targeting patients with **mild cognitive impairment** linked to hard-to-treat neurodegenerative conditions. The funding supports home-based treatment solutions combining evidence-based digital tools with remote clinical support.
Neuroglee Therapeutics launches a personalized AI-driven digital therapeutic platform targeting Alzheimer’s disease. The company secures $2.3 million in pre-seed funding to develop evidence-based digital treatments using AI, machine learning, and novel biomarkers. Its approach aims to slow neurodegenerative disease progression by tailoring interventions to individual patient needs.